Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.

Chi L, Peng YW, Gibson G, Hicks G, Mertz TE, Rapundalo S, Janiczek N, Edmunds JJ, Leadley R.

J Cardiovasc Pharmacol. 2004 Oct;44(4):493-500.

PMID:
15454859
2.

Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.

Willardsen JA, Dudley DA, Cody WL, Chi L, McClanahan TB, Mertz TE, Potoczak RE, Narasimhan LS, Holland DR, Rapundalo ST, Edmunds JJ.

J Med Chem. 2004 Jul 29;47(16):4089-99.

PMID:
15267248
3.

Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.

Chi L, Pen YW, Potoczak R, Gibson G, Hicks G, Mertz TE, Janiczek N, Juneau PL, Gallagher K, Leadley R.

Pharmacology. 2002 Feb;64(2):76-83.

PMID:
11803247
4.

The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.

McClanahan TB, Hicks GW, Morrison AL, Peng YW, Janiczek-Dolphin N, Mertz TE, Sullivan ME, Morser J, Juneau PL, Leadley R.

Eur J Pharmacol. 2001 Dec 7;432(2-3):187-94.

PMID:
11740955
5.

Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran.

Chi L, Mertz TE, Rogers KL, Janiczek N, Peng YW, Saganek L, Bousley RF, Juneau PL, Uprichard AC, Gallagher KP.

J Thromb Thrombolysis. 2001 Feb;11(1):19-31.

PMID:
11248787
6.

The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis.

McClanahan TB, Hicks GW, Ignasiak DP, Bousley R, Mertz TE, Juneau P, Janiczek-Dolphin N, Kim IC, Gallagher KP.

J Thromb Thrombolysis. 2000 Dec;10(3):277-84.

PMID:
11122549
7.

Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.

Dudley DA, Bunker AM, Chi L, Cody WL, Holland DR, Ignasiak DP, Janiczek-Dolphin N, McClanahan TB, Mertz TE, Narasimhan LS, Rapundalo ST, Trautschold JA, Van Huis CA, Edmunds JJ.

J Med Chem. 2000 Nov 2;43(22):4063-70.

PMID:
11063603
8.

A novel model of venous thrombosis in the vena cava of rabbits.

Chi L, Saganek LJ, Rogers KL, Mertz TE, Metz AL, Uprichard AC, Gallagher KP.

J Pharmacol Toxicol Methods. 1998 Jun;39(4):193-202.

PMID:
9845298
9.

Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs.

Janiczek N, Smith DE, Chang T, Ventura A, Mertz TE.

J Pharm Sci. 1997 Apr;86(4):443-9.

10.

Effects of endothelin-receptor antagonism with PD156707 on myocardial stunning in swine.

McClanahan TB, Mertz TE, Ignasiak DP, Juneau PL, Gallagher KP.

J Cardiovasc Pharmacol. 1996 Nov;28(5):679-86.

PMID:
8945682
11.

Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs.

Mertz TE, McClanahan TB, Flynn MA, Juneau P, Reynolds EE, Hallak H, Bradford L, Gallagher KP.

J Pharmacol Exp Ther. 1996 Jul;278(1):42-9.

PMID:
8764334
12.

Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound: morphologic features and pharmacokinetic and pharmacodynamic mechanisms.

Low JE, Metz AL, Mertz TE, Henry SP, Knowlton P, Loewen G, Sommers CS, Robertson DG, Olszewski BJ, Schroeder RL, et al.

J Cardiovasc Pharmacol. 1995 Jun;25(6):930-9.

PMID:
7564338
13.

Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs.

McClanahan TB, Ignasiak DP, Martin BJ, Mertz TE, Gallagher KP.

Basic Res Cardiol. 1995 Mar-Apr;90(2):176-83.

PMID:
7646420
14.

Does adenosine deaminase inhibition protect ischemic myocardium?

Gallagher KP, McClanahan TB, Martin BJ, Saganek LJ, Ignasiak DP, Mertz TE, Van Wylen DG, Vinten-Johansen J.

Adv Exp Med Biol. 1994;370:291-4. Review. No abstract available.

PMID:
7660911
15.

Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.

Hoefle ML, Blouin LT, Fleming RW, Hastings S, Hinkley JM, Mertz TE, Steffe TJ, Stratton CS, Werbel LM.

J Med Chem. 1991 Jan;34(1):7-12.

PMID:
1992154
16.

Synthesis and antiarrhythmic activity of cis-2,6-dimethyl-alpha,alpha-diaryl-1-piperidinebutanols.

Hoefle ML, Blouin LT, Fleming RW, Hastings S, Hinkley JM, Mertz TE, Steffe TJ, Stratton CS.

J Med Chem. 1991 Jan;34(1):12-9.

PMID:
1992110
17.

Pirmenol: preclinical pharmacology.

Kaplan HR, Mertz TE, Steffe TJ.

Angiology. 1988 Mar;39(3 Pt 2):281-92. Review.

PMID:
3281517
18.

Preclinical pharmacology of pirmenol.

Kaplan HR, Mertz TE, Steffe TJ.

Am J Cardiol. 1987 Jun 15;59(16):2H-9H.

PMID:
3591710
19.

CI-926 (3-[4-[4-(3-methylphenyl)-1-piperazinyl]butyl]-2,4-imidazolinedione): antihypertensive profile and pharmacology.

Ryan MJ, Bjork FA, Cohen DM, Coughenour LL, Major TC, Mathias NP, Mertz TE, Olszewski BJ, Singer RM, Evans DB, et al.

J Pharmacol Exp Ther. 1986 Aug;238(2):473-9.

PMID:
2874210
20.

Ribose-modified adenosine analogues as adenosine receptor agonists.

Taylor MD, Moos WH, Hamilton HW, Szotek DS, Patt WC, Badger EW, Bristol JA, Bruns RF, Heffner TG, Mertz TE.

J Med Chem. 1986 Mar;29(3):346-53.

PMID:
3005574
21.

CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.

Kaplan HR, Cohen DM, Essenburg AD, Major TC, Mertz TE, Ryan MJ.

Fed Proc. 1984 Apr;43(5):1326-9.

PMID:
6323223
22.

Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.

Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, Mertz TE, Olszewski BJ, Randolph AE, Singer RM, Kaplan HR.

J Pharmacol Exp Ther. 1984 Feb;228(2):312-8.

PMID:
6319675
23.
25.

Pirmenol hydrochloride (CI-845): antiarrhythmic profile in coronary artery ligated conscious dogs.

Mertz TE, Steffe TJ.

J Cardiovasc Pharmacol. 1980 Sep-Oct;2(5):527-41.

PMID:
6157947
26.

CL-845 (pirmenol hydrochloride): a new orally effective long-acting antiarrhythmic agent.

Steffe TJ, Mertz TE, Hastings SG, Potoczak RE, Kaplan HR.

J Pharmacol Exp Ther. 1980 Jul;214(1):50-7. No abstract available.

PMID:
7391970

Supplemental Content

Loading ...
Support Center